 Solid Biosciences Inc NASDAQ: SLDB reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 12 trial of SGT-001. SGT-001 is a novel adeno-associated viral AAV vector-mediated gene transfer therapy for Duchenne muscular dystrophy DMD. 